Floatz logo

Cetuximab

Liver Metastasis

EPS Corporationmonoclonal_antibodyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

16 Active assets in the Liver Metastasis cohort.

Asset / SponsorPhaseRating
Eloxatin
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Calcium folinate pentahydrate
National Taiwan University Hospital
Phase 3BB
FLUOROURACILUM
National Taiwan University Hospital
Phase 3BB
Talaporfin
Light Sciences LLC
Phase 2BB
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3B

View all 30 →

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →